Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

01-12-2020 | Oral Cancer | Research article

Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers

Authors: Chunmei Fan, Jinpeng Wang, Yanyan Tang, Shanshan Zhang, Fang Xiong, Can Guo, Yanhong Zhou, Zheng Li, Xiaoling Li, Yong Li, Guiyuan Li, Zhaoyang Zeng, Wei Xiong

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Identification of effective diagnostic and prognostic biomarkers of cancer is necessary for improving precision medicine. Long non-coding RNAs (lncRNAs) play an important regulatory role in tumor initiation and progression. The lncRNA LOC284454 is distinctly expressed in various head and neck cancers (HNCs), as demonstrated by our previous bioinformatics analysis. However, the expression levels and functions of LOC284454 in cancer are still unclear.

Methods

We investigated the dysregulation of lncRNAs in HNCs using the GEO database and found that LOC284454 was highly expressed in HNCs. Serum samples from 212 patients with HNCs and 121 normal controls were included in this biomarker study. We measured the expression of LOC284454 in the sera of HNC patients and normal controls using RT-qPCR. Receiver operating characteristics (ROC) analysis is an important statistical method that is widely used in clinical diagnosis and disease screening. ROC was used to analyze the clinical value of LOC284454 in the early diagnosis of HNCs.

Results

LOC284454 was significantly upregulated in the sera of patients with nasopharyngeal carcinoma, oral cancer, and thyroid cancer. LOC284454 upregulation had good clinical diagnostic value in these cancers, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834, respectively.

Conclusions

LOC284454 may be a valuable serum biomarker for HNCs facilitating the early diagnosis of malignant cancers. Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs. This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.
Appendix
Available only for authorised users
Literature
1.
Androvic P, Valihrach L, Elling J, et al. Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification. Nucleic Acids Res. 2017;45:e144.PubMedPubMedCentralCrossRef
2.
Bo H, Fan L, Gong Z, et al. Upregulation and hypomethylation of lncRNA AFAP1AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. Oncol Rep. 2019.
3.
Bo H, Fan L, Li J, et al. High expression of lncRNA AFAP1-AS1 promotes the progression of Colon Cancer and predicts poor prognosis. J Cancer. 2018;9:4677–83.PubMedPubMedCentralCrossRef
4.
Bo H, Gong Z, Zhang W, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6:20404–18.PubMedPubMedCentralCrossRef
5.
6.
Cui M, Chang Y, Du W, et al. Upregulation of lncRNA-ATB by transforming growth factor beta1 (TGF-beta1) promotes migration and invasion of papillary thyroid carcinoma cells. Med Sci Monit. 2018;24:5152–8.PubMedPubMedCentralCrossRef
7.
Das M, Renganathan A, Dighe SN, et al. DDX5/p68 associated lncRNA LOC284454 is differentially expressed in human cancers and modulates gene expression. RNA Biol. 2018;15:214–30.PubMedCrossRef
8.
9.
10.
11.
Fan C, Tang Y, Wang J, et al. Long non-coding RNA LOC284454 promotes migration and invasion of nasopharyngeal carcinoma via modulating the rho/Rac signaling pathway. Carcinogenesis. 2019;40:380–91.PubMedCrossRef
12.
13.
14.
Fernandes TJR, Costa J, Oliveira M, et al. Exploiting 16S rRNA gene for the detection and quantification of fish as a potential allergenic food: a comparison of two real-time PCR approaches. Food Chem. 2018;245:1034–41.PubMedCrossRef
15.
Ge J, Wang J, Wang H, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11:932–9.PubMedPubMedCentralCrossRef
16.
Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317–25.PubMedCrossRef
17.
Gong Z, Yang Q, Zeng Z, et al. An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma. Tumour Biol. 2016;37:3683–95.PubMedCrossRef
18.
Gong Z, Zhang S, Zeng Z, et al. LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2. PLoS One. 2014;9:e110674.PubMedPubMedCentralCrossRef
19.
Gong Z, Zhang S, Zhang W, et al. Long non-coding RNAs in cancer. Sci China Life Sci. 2012;55:1120–4.PubMedCrossRef
20.
Han Y, Hou SY, Ji SZ, et al. A novel method of multiple nucleic acid detection: real-time RT-PCR coupled with probe-melting curve analysis. Anal Biochem. 2017;537:50–5.PubMedCrossRef
21.
He B, Li W, Wu Y, et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103. Cell Death Dis. 2016;7:e2353.PubMedPubMedCentralCrossRef
22.
He B, Zeng J, Chao W, et al. Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 AS diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget. 2017;8:41166–77.PubMedPubMedCentralCrossRef
23.
He Y, Jing Y, Wei F, et al. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. Cell Death Dis. 2018;9:235.PubMedPubMedCentralCrossRef
24.
Huangfu H, Xu W, Wang H, et al. Detection of Gallibacterium anatis by TaqMan fluorescent quantitative PCR. Avian pathology : journal of the WVPA. 2018;47:245–52.CrossRef
25.
Jin K, Wang S, Zhang Y, et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. Cell Mol Life Sci. 2019;76:4275–89.PubMedPubMedCentralCrossRef
26.
Karlsson O, Rodosthenous RS, Jara C , et al. Detection of long non-coding RNAs in human breastmilk extracellular vesicles: implications for early child development. Epigenetics 2016: 0.
27.
Kogure T, Yan IK, Lin WL, et al. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular Cancer. Genes Cancer. 2013;4:261–72.PubMedPubMedCentralCrossRef
28.
Li Q, Chen P, Zeng Z, et al. Yeast two-hybrid screening identified WDR77 as a novel interacting partner of TSC22D2. Tumour Biol. 2016;37:12503–12.PubMedCrossRef
29.
Lian Y, Xiong F, Yang L, et al. Long noncoding RNA AFAP1-AS1 acts AS a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the rho/Rac pathway. J Exp Clin Cancer Res. 2018;37:253.PubMedPubMedCentralCrossRef
30.
Liang F, Li Q, Li X, et al. TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer. Int J Oncol. 2016;49:1046–56.PubMedCrossRef
31.
Liao Q, Guo X, Li X, et al. Prohibitin is an important biomarker for nasopharyngeal carcinoma progression and prognosis. Eur J Cancer Prev. 2013;22:68–76.PubMedCrossRef
32.
Liao Q, Zeng Z, Guo X, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene. 2014;33:2098–109.PubMedCrossRef
33.
Mo Y, Wang Y, Xiong F, et al. Proteomic analysis of the molecular mechanism of lovastatin inhibiting the growth of nasopharyngeal carcinoma cells. J Cancer. 2019;10:2342–9.PubMedPubMedCentralCrossRef
34.
35.
Pefanis E, Wang J, Rothschild G, et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 2015;161:774–89.PubMedPubMedCentralCrossRef
36.
37.
Qiu L, Chen MM, Wan XY, et al. Detection and quantification of shrimp hemocyte iridescent virus by TaqMan probe based real-time PCR. J Invertebr Pathol. 2018;154:95–101.PubMedCrossRef
38.
Ren D, Hua Y, Yu B, et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:19.PubMedPubMedCentralCrossRef
39.
Song Y, Li X, Zeng Z, et al. Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1. Oncotarget. 2016;7:36783–99.PubMedPubMedCentralCrossRef
40.
Su Y, Liu Y, Chen Y, et al. A novel duplex TaqMan probe-based real-time RT-qPCR for detecting and differentiating classical and variant porcine epidemic diarrhea viruses. Mol Cell Probes. 2018;37:6–11.PubMedCrossRef
41.
42.
Tu C, Zeng Z, P Q, et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole genome sequencing. Carcinogenesis. 2018;39(12):1517.PubMedCrossRef
43.
Tu C, Zeng Z, Qi P, et al. Genome-wide analysis of 18 Epstein-Barr viruses isolated from primary nasopharyngeal carcinoma biopsy specimens. J Virol. 2017;91.
44.
Wang D, Tang L, Y W, et al. Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci. 2020;10:1.
45.
Wang J, Shao N, Ding X, et al. Crosstalk between transforming growth factor-beta signaling pathway and long non-coding RNAs in cancer. Cancer Lett. 2016;370:296–301.PubMedCrossRef
46.
Wang JP, Tang YY, Fan CM, et al. The role of exosomal non-coding RNAs in cancer metastasis. Oncotarget. 2018;9:12487–502.PubMedCrossRef
47.
48.
49.
50.
Wei F, Tang L, He Y, et al. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell Death Dis. 2018;9:432.PubMedPubMedCentralCrossRef
51.
Wei F, Wu Y, Tang L, et al. Trend analysis of cancer incidence and mortality in China. Sci China Life Sci. 2017;60:1271–5.PubMedCrossRef
52.
Wu C, Li M, H M, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62(5):640.PubMedCrossRef
53.
54.
55.
Xiao L, Wei F, Liang F, et al. TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing. Carcinogenesis. 2019;40:819–27.PubMedCrossRef
56.
Xiong F, Deng S, Huang HB, et al. Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. Chin Med J. 2019;132:749–52.PubMedPubMedCentralCrossRef
57.
Zhang W, Huang C, Gong Z, et al. Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. J Mol Histol. 2013;44:545–54.PubMedCrossRef
58.
Zhou Y, Liao Q, Li X, et al. HYOU1, regulated by LPLUNC1, is up-regulated in nasopharyngeal carcinoma and associated with poor prognosis. J Cancer. 2016;7:367–76.PubMedPubMedCentralCrossRef
Metadata
Title
Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers
Authors
Chunmei Fan
Jinpeng Wang
Yanyan Tang
Shanshan Zhang
Fang Xiong
Can Guo
Yanhong Zhou
Zheng Li
Xiaoling Li
Yong Li
Guiyuan Li
Zhaoyang Zeng
Wei Xiong
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07408-w

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

An integrated autophagy-related gene signature predicts prognosis in human endometrial Cancer

Research article

Bioinformatic analysis reveals hub genes and pathways that promote melanoma metastasis

Research article

The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study

Research article

Survival analysis of patients with stage T2a and T2b perihilar cholangiocarcinoma treated with radical resection

Research article

Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model

Research article

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits